Cargando…

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia

Toll-like receptor 4 (TLR4) is a pattern-recognizing receptor that can bind exogenous and endogenous ligands. It is expressed by acute myeloid leukemia (AML) cells, several bone marrow stromal cells, and nonleukemic cells involved in inflammation. TLR4 can bind a wide range of endogenous ligands tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruserud, Øystein, Reikvam, Håkon, Brenner, Annette Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838156/ https://www.ncbi.nlm.nih.gov/pubmed/35163998 http://dx.doi.org/10.3390/molecules27030735

Ejemplares similares

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia
por: Johansen, Silje, et al.
Publicado: (2018)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms
por: Brenner, Annette K., et al.
Publicado: (2014)

Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype
por: Brenner, Annette K., et al.
Publicado: (2019)

CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors
por: Brenner, Annette K., et al.
Publicado: (2017)

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism
por: Nepstad, Ina, et al.
Publicado: (2018)

S100 Proteins in Acute Myeloid Leukemia()()
por: Brenner, Annette K., et al.
Publicado: (2018)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients
por: Johansen, Silje, et al.
Publicado: (2018)

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder
por: Bruserud, Øyvind, et al.
Publicado: (2020)

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
por: Reikvam, Håkon, et al.
Publicado: (2019)

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells
por: Aasebø, Elise, et al.
Publicado: (2021)

Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro Stress
por: Ryningen, Anita, et al.
Publicado: (2012)

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Clinical proteomics of myeloid leukemia
por: Hjelle, Sigrun M, et al.
Publicado: (2010)

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2013)

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020)

Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles
por: REIKVAM, HÅKON, et al.
Publicado: (2015)

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
por: Reikvam, Håkon, et al.
Publicado: (2022)

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
por: Nepstad, Ina, et al.
Publicado: (2018)

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation
por: Bruserud, Øystein, et al.
Publicado: (2021)

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
por: Brenner, Annette K., et al.
Publicado: (2017)

Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid
por: Ersvaer, Elisabeth, et al.
Publicado: (2015)

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid
por: Hernandez-Valladares, Maria, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation
por: Reikvam, Håkon, et al.
Publicado: (2015)

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment
por: Hansen, Bent-Are, et al.
Publicado: (2019)

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
por: Bartaula-Brevik, Sushma, et al.
Publicado: (2023)

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation
por: Bruserud, Øystein, et al.
Publicado: (2014)

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2021)

Role of Nucleophosmin Gene Mutation in Leukemogenesis of Acute Myeloid Leukemia
por: Khaled, Safaa A.A., et al.
Publicado: (2018)

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
por: Lee-Sherick, A B, et al.
Publicado: (2013)

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients
por: Bruserud, Øystein, et al.
Publicado: (2023)

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia
por: Andresen, Vibeke, et al.
Publicado: (2016)

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
por: Haaland, Ingvild, et al.
Publicado: (2014)

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators
por: Aasebø, Elise, et al.
Publicado: (2018)

Erratum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
por: Lee-Sherick, A B, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uihckmgqatq5irbvqg8tm0d2ct